The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts.

Hall, Ronald G; Cole, Travis J; Shaw, Chip; Alvarez, Carlos A

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts.

Hall, Ronald G; Cole, Travis J; Shaw, Chip; Alvarez, Carlos A.

Afiliación

Hall RG; Department of Pharmacy Practice, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75235, USA.
Cole TJ; Clinical Research Data Warehouse, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Shaw C; Clinical Research Data Warehouse, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Alvarez CA; Department of Pharmacy Practice, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75235, USA.

Antibiotics (Basel) ; 11(3)2022 Feb 23.

Article en En | MEDLINE | ID: mdl-35326759

Palabras clave

CDI; Clostridioides difficile; fidaxomicin; recurrence; vancomycin

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Antibiotics (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google